株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血小板減少症 (免疫性、化学療法誘発性) の世界市場:考察・動向・将来予測

Global Thrombocytopenia (Immune & Chemotherapy-induced) Market: Insights, Trends and Forecast (2019-2023)

発行 Koncept Analytics 商品コード 910605
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
血小板減少症 (免疫性、化学療法誘発性) の世界市場:考察・動向・将来予測 Global Thrombocytopenia (Immune & Chemotherapy-induced) Market: Insights, Trends and Forecast (2019-2023)
出版日: 2019年09月06日 ページ情報: 英文 95 Pages
概要

当レポートでは、世界の血小板減少症の市場について分析し、全体的な市場規模の動向見通し (今後5年間分) や、種類別 (免疫性血小板減少症 (ITP)、化学療法誘発性血小板減少症 (CIT) など) および地域別の詳細動向、主な市場促進・抑制要因、企業間の競争状態・業績比較、主要企業のプロファイルなどを調査しております。

第1章 概要

第2章 世界の血小板減少症市場

  • 免疫性血小板減少症 (ITP) 市場
    • 市場規模 (金額ベース、予測値)
    • 患者数 (人数、予測値)
    • 患者数:地域別 (人数、予測値)
    • 治療済み患者数 (人数、予測値)
    • 治療済み患者数:地域別 (人数、予測値)
  • 化学療法誘発性血小板減少症 (CIT) 市場
    • 患者数 (人数、予測値)
    • 患者数:地域別 (人数、予測値)
    • 治療済み患者数 (人数、予測値)
    • 治療済み患者数:地域別 (人数、予測値)

第3章 各地域の血小板減少症市場

  • 米国市場
    • ITP (免疫性血小板減少症):患者総数の予測
    • ITP:治療済み患者数の予測
    • ITP:Dopteletで治療した患者数の予測
    • CIT (化学療法誘発性血小板減少症):患者総数の予測
    • CIT:治療済み患者数の予測
    • CIT:Dopteletで治療した患者数の予測
    • CLD (慢性肝疾患):患者数の予測
    • CLD:重度の血小板減少症を併発した患者数の予測
    • CLD:重度の血小板減少症を併発した、治療済み患者数の予測
  • 他の国々 (RoW) の市場
    • ITP:患者総数の予測
    • ITP:治療済み患者数の予測
    • CIT:患者総数の予測
    • CIT:治療済み患者数の予測

第4章 市場のダイナミクス

  • 成長促進要因
  • 主な傾向と動静
  • 課題

第5章 競争環境

  • 世界市場
    • 主要企業:現在提供可能な、慢性血小板減少症向け医薬品
    • 主要企業:研究開発 (R&D) の比較
    • 主要企業:市場収益額の比較
    • 主要企業:株式時価総額の比較

第6章 企業プロファイル

  • Novartis AG
    • 事業概要
    • 主な財務指標
    • 事業戦略
  • Merck & Co.
  • Amgen Inc.
  • CSL Limited
  • Horizon Therapeutics
  • Rigel Pharmaceuticals
目次

The global immune thrombocytopenia (ITP) market is expected to reach 2.27 billion in 2023, growing at a CAGR of 5.82%, for the duration spanning 2019-2023. The factors such as, rising healthcare expenditures, growing female population, rising prevalence of arthritis, increasing incidences of hepatitis C and new cases of diagnosed cancer would drive the growth of the market. However, market growth would be challenged by the lethargic drug approval process, side effects associated with available thrombocytopenia drugs and the availability of alternative treatment options. A few notable trends include, novel drug development for thrombocytopenia, increasing number of awareness programs against thrombocytopenia, and increasing preferences for biosimilars.

The global thrombocytopenia market would witness considerable growth in coming years, due to the rising prevalence of thrombocytopenia and associated risk factors. The most common type of thrombocytopenia is ITP, which is highly prevalent in patients with rheumatoid arthritis. Whereas, CIT (Chemotherapy-Induced Thrombocytopenia) occurs in patients with cancer, due to the involvement of chemotherapy and radiation treatment. Thrombocytopenia in patients with CLD is growing rapidly with an increase in incidences of HCV infections among them.

The fastest growing regional market is the U.S., owing to the high prevalence of thrombocytopenia in patients with cancer as well as chronic liver diseases. Moreover, rising awareness about the symptoms and causes of thrombocytopenia among people, through various campaigns and the FDA approvals of various novel drugs for the treatment of thrombocytopenia would drive considerable growth in the global thrombocytopenia market.

Scope of the report:

The report provides a comprehensive analysis of the global thrombocytopenia (Immune and Chemotherapy-induced) market.

The major regional market (the U.S.) has been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Novartis AG, Merck and Co., CSL Limited, Amgen Pharmaceuticals, Horizon Therapeutics and Rigel Pharmaceuticals) are also presented in detail.

Key Target Audience:

  • Thrombocytes Drugs Manufacturers
  • Chemical Suppliers
  • End Users (Hospital, Medical Centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Overview

  • 1.1 Introduction
  • 1.2 Causes of Thrombocytopenia
  • 1.3 Symptoms of Thrombocytopenia
  • 1.4 Diagnosis of Thrombocytopenia
  • 1.5 Treatment of Thrombocytopenia
  • 1.6 Pathophysiology of Thrombocytopenia

2. Global Thrombocytopenia Market

  • 2.1 Global ITP Market
    • 2.1.1 Global ITP Market Forecast by Value
    • 2.1.2 Global ITP Total Patient Volume Forecast
    • 2.1.3 Global ITP Total Patient Volume Forecast by Region
    • 2.1.4 Global ITP Treated Patient Volume Forecast
    • 2.1.5 Global ITP Treated Patient Volume Forecast by Region
  • 2.2 Global CIT Market
    • 2.2.1 Global CIT Total Patient Volume Forecast
    • 2.2.2 Global CIT Total Patient Volume Forecast by Region
    • 2.2.3 Global CIT Treated Patient Volume Forecast
    • 2.2.4 Global CIT Treated Patient Volume Forecast by Region

3. Regional Thrombocytopenia Market

  • 3.1 The U.S.
    • 3.1.1 The U.S. ITP Total Patient Volume Forecast
    • 3.1.2 The U.S. ITP Treated Patient Volume Forecast
    • 3.1.3 The U.S. Doptelet ITP Treated Patient Volume Forecast
    • 3.1.4 The U.S. CIT Total Patient Volume Forecast
    • 3.1.5 The U.S. CIT Treated Patient Volume Forecast
    • 3.1.6 The U.S. Doptelet CIT Treated Patient Volume Forecast
    • 3.1.7 The U.S. CLD Patient Volume Forecast
    • 3.1.8 The U.S. CLD Patient Volume with Severe Thrombocytopenia Forecast
    • 3.1.9 The U.S. CLD Treated Patient Volume with Severe Thrombocytopenia Forecast
  • 3.2 ROW (Rest of World)
    • 3.2.1 ROW ITP Total Patient Volume Forecast
    • 3.2.2 ROW ITP Treated Patient Volume Forecast
    • 3.2.3 ROW CIT Total Patient Volume Forecast
    • 3.2.4 ROW CIT Treated Patient Volume Forecast

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Rising HealthCare Expenditure
    • 4.1.2 Growing Female Population
    • 4.1.3 Rising Prevalence of Arthritis
    • 4.1.4 Increasing Incidences of Hepatitis C
    • 4.1.5 New Cases of Diagnosed Cancer
  • 4.2 Key Trends & Development
    • 4.2.1 Novel Drug Development for Thrombocytopenia
    • 4.2.2 Increasing Number of Awareness Programs about Thrombocytopenia
    • 4.2.3 Increase in Pharmaceutical R&D Expenditures
    • 4.2.4 Increasing Preference for Biosimilars
  • 4.3 Challenges
    • 4.3.1 Lethargic Drug Approval Process
    • 4.3.2 Side Effects Associated With Available Thrombocytopenia Drugs
    • 4.3.3 Availability of Alternative Treatment Options

5. Competitive Landscape

  • 5.1 Global Market
    • 5.1.1 Key Players - Available Drugs for Chronic Thrombocytopenia
    • 5.1.2 Key Players - R&D Comparison
    • 5.1.3 Key Players - Revenue Comparison
    • 5.1.4 Key Players - Market Cap Comparison

6. Company Profiles

  • 6.1 Novartis AG
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Merck & Co.
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Amgen Inc.
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 CSL Limited
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies
  • 6.5 Horizon Therapeutics
    • 6.5.1 Business Overview
    • 6.5.2 Financial Overview
    • 6.5.3 Business Strategies
  • 6.6 Rigel Pharmaceuticals
    • 6.6.1 Business Overview
    • 6.6.2 Financial Overview
    • 6.6.3 Business Strategies

List of Figures

  • Symptoms of Thrombocytopenia
  • Diagnosis of Thrombocytopenia
  • Treatment of Thrombocytopenia
  • Global ITP Market Forecast by Value (2019-2023)
  • Global Total ITP Total Patient Volume Forecast (2019-2023)
  • Global ITP Total Patient Volume Forecast by Region (2023)
  • Global ITP Treated Patient Volume Forecast (2019-2023)
  • Global ITP Treated Patient Volume Forecast by Region (2023)
  • Global CIT Total Patient Volume Forecast (2019-2023)
  • Global CIT Total Patient Volume Forecast by Region (2018/2023)
  • Global CIT Treated Patient Volume Forecast (2018-2023)
  • Global CIT Treated Patient Volume Forecast by Region (2018/2023)
  • The U.S. ITP Total Patient Volume Forecast (2019-2023)
  • The U.S. ITP Treated Patient Volume Forecast (2019-2023)
  • The U.S. Doptelet ITP Treated Patient Volume Forecast (2019-2023)
  • The U.S. CIT Total Patient Volume Forecast (2018-2023)
  • The U.S. CIT Treated Patient Volume Forecast (2018-2023)
  • The U.S. Doptelet CIT Treated Patient Volume Forecast (2021-2026)
  • The U.S. CLD Patient Volume Forecast (2018-2023)
  • The U.S. CLD Patient Volume with Severe Thrombocytopenia Forecast (2018-2023)
  • The U.S. CLD Treated Patient Volume with Severe Thrombocytopenia Forecast (2018-2023)
  • ROW ITP Total Patient Volume Forecast (2019-2023)
  • ROW ITP Treated Patient Volume Forecast (2019-2023)
  • ROW CIT Total Patient Volume Forecast (2018-2023)
  • ROW CIT Treated Patient Volume Forecast (2018-2023)
  • Global HealthCare Expenditure Per Capita (2014-2018)
  • Global Female Population (2014-2018)
  • Novel Drug Development for Thrombocytopenia (2018)
  • Awareness Programs about Thrombocytopenia (2018)
  • Global Pharmaceutical R&D Expenditures (2014-2018)
  • Drugs Approval Process
  • Key Players - R&D Comparison (2017-2018)
  • Novartis AG Net Sales and Net Income (2014-2018)
  • Novartis AG Net Sales by Segment (2018)
  • Novartis AG Net Sales by Regions (2018)
  • Merck & Co. Sales and Net Income (2014-2018)
  • Merck & Co. Sales by Segment (2018)
  • Merck & Co. Sales by Regions (2018)
  • Amgen Inc. Total Revenue and Net Income (2014-2018)
  • Amgen Inc. Total Revenue by Segment (2018)
  • Amgen Inc. Total Revenue by Regions (2018)
  • CSL Limited Total Operating Revenue and Net Profit (2014-2018)
  • CSL Limited Total Operating Revenue by Segment (2018)
  • CSL Limited Total Operating Revenue by Regions (2018)
  • Horizon Therapeutics Net Sales and Net Loss (2014-2018)
  • Horizon Therapeutics Net Sales by Segment (2018)
  • Horizon Therapeutics Net Sales by Regions (2018)
  • Rigel Pharmaceuticals Total Revenue and Net Loss (2014-2018)
  • Rigel Pharmaceuticals Total Revenue by Divisions (2018)

List of Tables

  • Causes of Thrombocytopenia
  • The U.S. Diagnosed Arthritis Population (2000-2020)
  • Hepatitis C Population in Major Regions (2018)
  • Global New Cases of Diagnosed Cancer (2018)
  • Key Players - Available Drugs for Chronic Thrombocytopenia
  • Key Players - Revenue Comparison (2018)
  • Key Players - Market Cap Comparison (2019)
Back to Top